Internal medicine, Surgery, Gastroenterology, Cancer research and Lymphoma are his primary areas of study. Internal medicine is closely attributed to Oncology in his work. His Gastroenterology study which covers Survival analysis that intersects with Interleukin.
The Cancer research study combines topics in areas such as Immunology, Cytokine, Apoptosis, Programmed cell death and Signal transduction. In his study, which falls under the umbrella issue of Lymphoma, CD40 is strongly linked to Chronic lymphocytic leukemia. His Transplantation research incorporates elements of Preparative Regimen, Nivolumab, Neutropenia and Hodgkin's lymphoma.
His scientific interests lie mostly in Internal medicine, Lymphoma, Oncology, Cancer research and Surgery. His research in Internal medicine tackles topics such as Gastroenterology which are related to areas like Non-Hodgkin's lymphoma. Immunology and Pathology are inextricably linked to his Lymphoma research.
His work deals with themes such as Clinical trial, Neutropenia, Refractory and Hodgkin lymphoma, which intersect with Oncology. His research integrates issues of Apoptosis, Protein kinase B, PI3K/AKT/mTOR pathway and Programmed cell death in his study of Cancer research. His Rituximab research is multidisciplinary, incorporating perspectives in Progression-free survival, Vincristine, Cyclophosphamide, Follicular lymphoma and Prednisone.
Anas Younes focuses on Internal medicine, Oncology, Lymphoma, Cancer research and Rituximab. His study in Brentuximab vedotin, Follicular lymphoma, Chemotherapy, Chemotherapy regimen and ABVD falls under the purview of Internal medicine. His work in Oncology covers topics such as Nivolumab which are related to areas like Hematopoietic stem cell transplantation.
His Lymphoma study combines topics from a wide range of disciplines, such as Venetoclax and Cancer. His study looks at the relationship between Cancer research and topics such as Hodgkin lymphoma, which overlap with Clinical trial. His Rituximab study integrates concerns from other disciplines, such as Progression-free survival, Gastroenterology, Prednisone and Vincristine, Cyclophosphamide.
His main research concerns Internal medicine, Oncology, Lymphoma, Cancer research and Brentuximab vedotin. Anas Younes combines Internal medicine and Population in his research. His Oncology research is multidisciplinary, incorporating elements of Classical Hodgkin lymphoma, Clinical trial, Refractory, Mantle cell lymphoma and Advanced stage.
His biological study spans a wide range of topics, including Cancer and Histone deacetylase inhibitor. His Cancer research study incorporates themes from Bromodomain, Immune system, Diffuse large B-cell lymphoma, MHC class I and Bruton's tyrosine kinase. His Brentuximab vedotin research is multidisciplinary, relying on both Chlorambucil and ABVD.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Guidelines for the use and interpretation of assays for monitoring autophagy
Daniel J. Klionsky;Fabio C. Abdalla;Hagai Abeliovich;Robert T. Abraham.
Results of a Pivotal Phase II Study of Brentuximab Vedotin for Patients With Relapsed or Refractory Hodgkin's Lymphoma
Anas Younes;Ajay K. Gopal;Scott E. Smith;Stephen M. Ansell.
Journal of Clinical Oncology (2012)
Brentuximab Vedotin (SGN-35) for Relapsed CD30-Positive Lymphomas
Anas Younes;Nancy L Bartlett;John P Leonard;Dana A Kennedy.
The New England Journal of Medicine (2010)
Standards and Guidelines for the Interpretation and Reporting of Sequence Variants in Cancer: A Joint Consensus Recommendation of the Association for Molecular Pathology, American Society of Clinical Oncology, and College of American Pathologists
Marilyn M. Li;Michael Datto;Eric J. Duncavage;Shashikant Kulkarni.
The Journal of Molecular Diagnostics (2017)
Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial
Anas Younes;Armando Santoro;Margaret Shipp;Pier Luigi Zinzani.
Lancet Oncology (2016)
High Rate of Durable Remissions After Treatment of Newly Diagnosed Aggressive Mantle-Cell Lymphoma With Rituximab Plus Hyper-CVAD Alternating With Rituximab Plus High-Dose Methotrexate and Cytarabine
Jorge E. Romaguera;Luis Fayad;Maria A. Rodriguez;Kristine R. Broglio.
Journal of Clinical Oncology (2005)
Guidelines for the Management of Pediatric and Adult Tumor Lysis Syndrome: An Evidence-Based Review
Bertrand Coiffier;Arnold Altman;Ching-Hon Pui;Anas Younes.
Journal of Clinical Oncology (2008)
Phase II Study of Proteasome Inhibitor Bortezomib in Relapsed or Refractory B-Cell Non-Hodgkin's Lymphoma
Andre Goy;Anas Younes;Peter McLaughlin;Barbara Pro.
Journal of Clinical Oncology (2005)
Nonablative allogeneic hematopoietic transplantation as adoptive immunotherapy for indolent lymphoma: low incidence of toxicity, acute graft-versus-host disease, and treatment-related mortality
Issa F. Khouri;Rima M. Saliba;Sergio A. Giralt;Ming Sheng Lee.
Activation of the sphingomyelin signaling pathway in intact EL4 cells and in a cell-free system by IL-1 beta
Shalini Mathias;Anas Younes;Chu-Cheng Kan;Irene Orlow.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: